Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration

BACKGROUND. Uterine leiomyosarcoma (uLMS) responds poorly to conventional chemotherapeutic agents, and personalized therapies have yet to be systematically explored. Comprehensive genomic profiling (CGP) can identify therapeutic targets and provide insight into the biology of this highly aggressive...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Elvin, Julia A., Gay, Laurie M., Ort, Rita, Shuluk, Joseph, Long, Jennifer, Shelley, Lauren, Lee, Ronald, Chalmers, Zachary R., Frampton, Garrett M., Ali, Siraj M., Schrock, Alexa B., Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S., Frank, Richard
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Gynecologic Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388371/
https://ncbi.nlm.nih.gov/pubmed/28283584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0310
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars